AngioDynamics Timeline

Company Founded
Company is founded as a division of E-Z-EM Inc. dedicated to the research and development of products used in interventional radiology.
Product Shipments Begin
Product shipments begin, and the company soon becomes well established as a producer of diagnostic catheters for non-coronary angiography and thrombolytic delivery systems.
Subsidiary of E-Z-EM

The company is organized in the state of Delaware under the name A.D. Inc. and as a wholly owned subsidiary of E-Z-EM.

Name Changes to AngioDynamics
Name officially changes to AngioDynamics Inc. after E-Z-EM transfers its A.D. division to the subsidiary.
Eamonn P. Hobbs - President
June 1996

Eamonn P. Hobbs becomes president and chief executive officer of AngioDynamics.

Publically Traded
May 2004
AngioDynamics becomes publically traded on the NASDAQ stock exchange as ANGO.
E-Z-EM Distributes its Shares
October 2004
E-Z-EM distributes its shares of AngioDynamics common stock to its stockholders, completing the spinoff of AngioDynamics.
Common Stock Added to Russell 3000
June 2005

AngioDynamics common stock is added to the Russell 3000® index and the new Russell Microcap™ Index following Russell Investment Group’s reconstitution of its family of U.S. indices.

Founding Member of New NASDAQ Health Care Index
July 2005
AngioDynamics is chosen to be a founding member of the new NASDAQ Health Care Index
Total Abscession® Drainage Catheter
December 2005

Total Abscession – a general drainage catheter designed to percutaneously
drain abscesses and other fluid collections – is launched. It features the tamper-resistant  Vault® locking mechanism. This unique feature eliminates additional procedures to replace drainage catheters when the locking pigtail shape becomes unlocked during routine catheter maintenance. The Vault locking mechanism reduces physician time and increases patient comfort.

Business Weeks List of 100 Hot Growth Companies
April 2006

AngioDynamics is named to Business Week’s list of 100 Hot Growth Companies.

Morpheus® CT PICC Insertion Kit
May 2006

The Morpheus CT PICC insertion kit is launched nationwide. Use of the kit allows the AngioDynamics proprietary peripherally inserted central catheter (PICC) to be inserted at a patient’s bedside, instead of in the interventional radiology suite at the hospital, which is the current practice.

Follow-on public offering completed
May 2006

The follow-on public offering of AngioDynamics shares of common stock is completed.

Facility expansion announced in Queensbury
September 2006

AngioDynamics announces a facility expansion at the company’s Queensbury, N.Y., U.S., headquarters, consisting of a 36,000-square-foot warehouse and distribution center to accommodate its increasing number of employees and provide a foundation for future growth of the organization.

Oncobionic agreement
October 2006

AngioDynamics enters into a stock purchase agreement with Oncobionic Inc.

Forbes 200 Best Small Companies in America
October 2006

AngioDynamics is recognized as No. 11 on the Forbes 200 Best Small Companies in America list.

NanoKnife® receives 510(k) clearance from FDA
November 2006

AngioDynamics announces the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Oncobionic Inc. to market the NanoKnife® system – a technology indicated for surgical ablation of soft tissue, including cardiac and smooth muscle.

RITA acquisition announced
November 2006

AngioDynamics and RITA Medical System Inc. – a respected provider of medical oncology devices – announce the signing of a definitive agreement whereby AngioDynamics will acquire RITA.

RITA Acquisition Completed
January 2007

AngioDynamics completes the acquisition of RITA Medical Systems. The acquisition includes facilities in California and Georgia, increases the company’s total number of employees from around 200 to nearly 550 and gives AngioDynamics immediate access to the burgeoning interventional oncology market through RITA’s specialized sales force.

UniBlate™ RFA Electrode Launched
August 2007

RITA® UniBlate™ RFA Electrode – a scalable, single-needle radiofrequency ablation electrode used to coagulate lesions during percutaneous, laparoscopic and intraoperative surgical procedures – is launched.

Vincent Bucci Elected Board Chairman
August 2007

Vincent Bucci is elected chairman of the AngioDynamics Board of Directors. Mr. Bucci joined the AngioDynamics Board in January 2007 when AngioDynamics acquired RITA Medical Systems; he had been Chairman of the RITA Medical Systems Board since 2003 and a Board member since 1994.

AngioDynamics Marks 20th Anniversary
February 2008

AngioDynamics employees celebrate the company’s 20th Anniversary.

First Human Clinical Trial for NanoKnife® System
April 2008

The NanoKnife® system is successfully used in the first human clinical trial for the treatment of soft tissue.

Diomed Acquisition Announced
April 2008

AngioDynamics announces it has entered into an asset purchase agreements with Diomed Holdings Inc., Diomed Inc. and Diomed Limited for the acquisition of certain assets of Diomed’s business in the United States and United Kingdom.

Oncobionic Acquisition Completed
May 2008

Following the successful initial use of Oncobionic’s NanoKnife® system technology, AngioDynamics completes the acquisition of Oncobionic Inc. per the terms of the Oct. 12, 2006, agreement.

Diomed Acquisition Completed
June 2008

The acquisition of certain U.S. and U.K. assets of Diomed Ltd. Is completed, substantially strengthening the AngioDynamics’ position in the market for the treatment of varicose veins.

Business Reorganization
June 2008

AngioDynamics reorganizes into three business units – Peripheral Vascular, Access and Oncology/Surgery – to better serve its customers.

VenaCure EVLT™ System Launched
November 2008

The VenaCure EVLT System, a new varicose vein therapy brand, is launched at the American College of Phlebology (ACP) 22nd Annual Congress. The new brand encompasses the best of AngioDynamics’ VenaCure® product line, as well as the EVLT® procedure, a product line which AngioDynamics had recently rescued from the bankruptcy of Diomed Inc.

Leadership Development Plan Announced
December 2008

AngioDynamics announces the implementation of a leadership development plan combining succession planning with senior management team expansion. President and CEO Eamonn P. Hobbs announces he will be stepping down when a successor is identified.

Jan Keltjens Appointed President and CEO
January 2009

Jan Keltjens, an executive with more than 20 years of successful medical industry leadership experience, is appointed President and CEO of AngioDynamics.

Starburst® XLi-e Semi-Flex RFA Device
July 2009

The StarBurst® XLi-Enhanced Semi-Flex probe is the first radiofrequency ablation (RFA) device specifically designed to deliver a 7cm ablation of a tumor in a single placement during Computed Tomography-aided procedures.

DuraMax™ Chronic HemoDialysis Catheter
September 2009

AngioDynamics introduces the DuraMax stepped chronic dialysis catheter at the 2009 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Scientific Meeting, held in Lisbon, Portugal. The new catheter employs Curved Tip™ Catheter Technology that is designed to provide higher blood flow and lower recirculation, even if the catheter becomes positioned against a blood vessel wall. This design approach eliminates the need for side holes common in other catheters, reducing the potential for clots.

AngioDynamics Names Joseph M. DeVivo President and CEO
September 07 2011
Joseph M. DeVivo is appointed President and Chief Executive Officer of AngioDynamics. Prior to joining the Company, Mr. DeVivo served as Global President of Smith & Nephew Orthopedics (LSE: SN, NYSE: SNN) and previously served as President and Chief Executive Officer of RITA Medical Systems.
AngioDynamics to Acquire Navilyst Medical
January 31 2012
AngioDynamics enters into a definitive agreement to acquire privately-held Navilyst Medical,a global medical device company with particular strengths in the vascular access, interventional radiology and interventional cardiology markets. The acquisition will significantly expand AngioDynamics' scale, doubling its share of the Vascular Access market while building critical mass in the peripheral vascular market.
AngioDynamics Establishes Strategic Relationship with Microsulis Medical Ltd.
March 26 2012
AngioDynamics announces a strategic relationship with privately-held Microsulis Medical Ltd. – a medical device company specializing in minimally invasive, microwave ablation technology for the coagulation of soft tissue and has systems in more than 80 hospitals world-wide. The Company makes a $5 million equity investment in Microsulis through the purchase of senior preferred stock, representing a 14.3% ownership position, and is granted exclusive distribution rights to market and sell the Accu2i pMTA microwave ablation system in all markets outside the United States from May 2012 through December 2013, AngioDynamics also is granted the exclusive option to purchase, at any time until September 22, 2013, substantially all of the global assets of Microsulis Medical Ltd., including the microwave ablation technology and its worldwide distribution rights.
AngioDynamics Shareholders Approve Share Issuance for Navilyst Acquisition
May 15 2012
The Company's shareholders approve the issuance of approximately 9.5 million shares of AngioDynamics common stock for use in the acquisition of privately-held Navilyst Medical pursuant to the terms of the definitive acquisition agreement dated January 30, 2012.
AngioDynamics Completes Acquisition of Navilyst Medical
May 22 2012
AngioDynamics completes its acquisition of Navilyst Medical, with the transaction valued at $355 million. The combination of the two companies is expected to double AngioDynamics share of the vascular access market, build critical mass in the peripheral vascular market and establish a strong operating platform for future growth.